Search research articles
Contact Us
Filters
Showing results (551-560 of 643) with videos related to
Page
of 65
Sort By:
Gynecologic Oncology
|
July 30, 2020
Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial
Ana Oaknin, Claire F Friedman, Lynda D Roman, et al.
Journal of the Advanced Practitioner in Oncology
|
October 6, 2022
Management of Adverse Events in Early Clinical Trials by Advanced Practice Providers in the Outpatient Setting: The University of Texas MD Anderson Cancer Center Experience
Fedricker D Barber, Erick Campbell, Yuko Yamamura, et al.
Cancer Discovery
|
September 29, 2020
First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors
Timothy A Yap, David S P Tan, Angelika Terbuch, et al.
JAMA Oncology
|
December 11, 2025
Cognitive Impairment and Chemoendocrine vs Endocrine Therapy in Pre- and Postmenopausal Women: A Secondary Analysis of the RxPONDER Randomized Clinical Trial
Irene M Kang, Jamie K Forschmiedt, Michelle M Loch, et al.
JCO Precision Oncology
|
April 30, 2026
Nivolumab Plus Ipilimumab in Patients With Solid Tumors With High Tumor Mutation Burden: Results From the Targeted Agent and Profiling Utilization Registry Study
Erin F Cobain, Michael Rothe, Elizabeth Garrett-Mayer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 20, 2018
Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing
Thomas P Slavin, Kimberly C Banks, Darya Chudova, et al.
Oncotarget
|
May 19, 2015
Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies
Filip Janku, Philipp Angenendt, Apostolia M Tsimberidou, et al.
Oncotarget
|
September 26, 2015
Erratum: Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies
Filip Janku, Philipp Angenendt, Apostolia M Tsimberidou, et al.
Plos One
|
September 2, 2015
Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes
Priscilla F McAuliffe, Kurt W Evans, Argun Akcakanat, et al.
Scientific Reports
|
August 23, 2022
Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial
Tito R Mendoza, David S Hong, Christine B Peterson, et al.
Page
of 65
Search research articles
Search
Showing results (551-560 of 643) with videos related to
Sort By:
Page
of 65
Gynecologic Oncology
|
July 30, 2020
Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial
Ana Oaknin, Claire F Friedman, Lynda D Roman, et al.
Journal of the Advanced Practitioner in Oncology
|
October 6, 2022
Management of Adverse Events in Early Clinical Trials by Advanced Practice Providers in the Outpatient Setting: The University of Texas MD Anderson Cancer Center Experience
Fedricker D Barber, Erick Campbell, Yuko Yamamura, et al.
Cancer Discovery
|
September 29, 2020
First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors
Timothy A Yap, David S P Tan, Angelika Terbuch, et al.
JAMA Oncology
|
December 11, 2025
Cognitive Impairment and Chemoendocrine vs Endocrine Therapy in Pre- and Postmenopausal Women: A Secondary Analysis of the RxPONDER Randomized Clinical Trial
Irene M Kang, Jamie K Forschmiedt, Michelle M Loch, et al.
JCO Precision Oncology
|
April 30, 2026
Nivolumab Plus Ipilimumab in Patients With Solid Tumors With High Tumor Mutation Burden: Results From the Targeted Agent and Profiling Utilization Registry Study
Erin F Cobain, Michael Rothe, Elizabeth Garrett-Mayer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 20, 2018
Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing
Thomas P Slavin, Kimberly C Banks, Darya Chudova, et al.
Oncotarget
|
May 19, 2015
Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies
Filip Janku, Philipp Angenendt, Apostolia M Tsimberidou, et al.
Oncotarget
|
September 26, 2015
Erratum: Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies
Filip Janku, Philipp Angenendt, Apostolia M Tsimberidou, et al.
Plos One
|
September 2, 2015
Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes
Priscilla F McAuliffe, Kurt W Evans, Argun Akcakanat, et al.
Scientific Reports
|
August 23, 2022
Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial
Tito R Mendoza, David S Hong, Christine B Peterson, et al.
Page
of 65